Additional Information

Overview
This CME monograph, authored by five leaders in bone cancer research and treatment, reviews new clinical data and recommendations related to the use of bone-targeted therapies to treat and prevent bone metastasis and prevent bone loss related to cancer treatment, and integrate this information into their own practice.

Learning Objectives

• Discuss and assess appropriate use of bone-targeted agents to treat bone metastasis and its complications in cancer patients.
• Discuss and assess current data on potential role of bone- targeted agents in preventing bone metastasis.
• Discuss and assess appropriate use of bone-targeted agents to prevent bone loss associated with cancer treatment.

Click on links below to access the online activity and the monograph.

Target Audience
Oncologists, urologists, and other medical professionals who assess, treat, or counsel cancer patients.

Faculty
Robert E. Coleman, MD, FRCP
Cancer Research Centre, Weston Park Hospital, Sheffield, UK

Theresa A. Guise, MD
Professor of Medicine Indiana University School of Medicine, Indianapolis, IN

Ingunn Holen, BSc, MSc, PhD
University of Sheffield Medical School, Sheffield, UK

Allan Lipton, MD
Professor of Medicine and Oncology, Penn State University, Hershey, PA

G. David Roodman, MD, PhD
VA Pittsburgh Healthcare System, Pittsburgh, PA

Educational Grant Support
Supported by educational grants provided by Amgen, Inc. and Novartis Pharmaceuticals.

Sponsorship
CME sponsorship and program management provided by InforMEDical Communications, Inc.

The CME activity has expired.